Acorda Therapeutics — Q3 2023 Earnings Presentation
19 slides from Acorda Therapeutics's earnings presentation, Nov 13, 2023
Slide 1: Acorda Therapeutics 2023 Q3 Earnings Call
Acorda Therapeutics 2023 Q3 Earnings Call November 13, 2023
Slide 2: Forward-Looking Statements
Forward-Looking Statements Forward-Looking Statements This presentation includes forward-looking statements. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or prospects should be considered forward-looking. These statements are s
Slide 3: Inbrija (levodopa inhalation powder) 42 mg capsules
Slide 4: INBRIJA U.S. Net Sales – Q3 2023
INBRIJA U.S. Net Sales – Q3 2023 $8.1M Q3 2023 net revenue 4% increase vs Q3 2022 4 2023 Q3 EARNINGS
Slide 5: INBRIJA U.S. Net Sales Trends Since Launch
INBRIJA U.S. Net Sales Trends Since Launch Net Sales Q1-3 2023 15% > vs Q1-3 2022 $M 12.0 4%> vs Q3 22 10.0 10.4 9.4 9.0 8.0 7.8 8.3 8.1 7.8 7.6 6.0 6.8 6.4 6.1 5.6 4.0 5.0 4.7 5.0 4.4 3.7 2.0 3.0 0.0 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2020 2021 2022 2023 5 2023 Q3 EARNINGS
Slide 6: INBRIJA Cartons Dispensed – Trends Since Launch
INBRIJA Cartons Dispensed – Trends Since Launch Cartons Dispensed to Patients Q1-3 2023 6.5% > vs Q1-3 2022 $M 4%> vs Q2 22 12000 10000 11029 10135 9924 10102 10227 9528 9349 9528 8000 8883 8737 9087 8514 8305 7857 7839 6000 6909 6955 4000 2000 0 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 20
Slide 7: INBRIJA TRX Trends Since Launch
INBRIJA TRX Trends Since Launch TRX Q1-3 2023 11% > vs Q1-3 2022 $M 10%> vs Q3 22 4000 3500 3793 3464 3546 3571 3000 3361 3319 3249 3300 3329 3110 3125 3077 2992 3070 2995 2500 2817 2761 2000 1915 1500 1000 500 79 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2019 2020 2021 2022 2023 7
Slide 8: INBRIJA TV Commercial Performing Well
INBRIJA TV Commercial Performing Well www.GetInbrija.com Airing on ~50 streaming services Paramount+, Hulu, Disney 9.3 million views since launch in April 2023 270 physicians prescribed for the first time in 2023 since seeing the commercial 8 2023 Q3 EARNINGS
Slide 9: INBRIJA Ex-U.S.
INBRIJA Ex-U.S. Latin America – 6 regulatory submissions complete – Potential for up to 5 approvals in 2024 Spain – surpassed apomorphine as leading on-demand treatment, good feedback from specialists Germany – hospital packs delivered, patient support program active for in- home visits from a nurse
Slide 10: Ampyra
\ ampyra’ ij q EXTENDED RELEASE TABLETS — Ampyra?
Slide 11: AMPYRA U.S. Net Sales – Q3 2023
AMPYRA U.S. Net Sales – Q3 2023 $15.7M Q3 2023 net revenue 26% decrease vs Q3 2022 11 2023 Q3 EARNINGS
Slide 12: Maintaining Branded AMPYRA
Maintaining Branded AMPYRA Net Sales, $MM $50.0 $44.2 $45.0 $40.6 $40.8 $40.0 $37.6 $35.0 $30.0 $27.2 -17% $25.8 $25.3 $25.0 $21.8 $22.5 $20.3 $20.0 $21.1 $19.9 $18.8 $20.0 $18.2 $16.9 $15.7 $14.9 $15.0 $12.6 $10.0 $5.0 $- Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2019 2019 2019 2019
Slide 13: Maintaining Branded AMPYRA
Maintaining Branded AMPYRA • Annual net sales expected to stabilize at ~$60M / year • Physician and patient brand loyalty has helped to maintain access • ~66% of all covered lives have access to AMPYRA1 • Field team continues to promote the brand • 210 HCPs have prescribed Brand in 2023 who did not
Slide 14: Financials
Financials 14 2023 Q3 EARNINGS
Slide 15: Q3 2023 Financial Summary
Q3 2023 Financial Summary Q/Q YTD YTD Y/Y ($ in millions) 3Q’23 3Q’22 Increase / September September Increase / (Decrease) 2023 2022 (Decrease) Net Global Inbrija Revenue 9.5 8.9 0.6 6.7% 24.6 21.9 2.7 12.3% Net Ampyra Revenue 15.7 21.1 (5.4) (25.6%) 45.2 54.2 (9.0) (16.6%) R&D 1.2 1.4 (0.2) (14.3%)
Slide 16: Q3 2023 Ex-U.S. Revenue
Q3 2023 Ex-U.S. Revenue INBRIJA ex-U.S. $ 1.4M FAMPYRA Royalty $ 2.5M • TOTAL EX-U.S.: $ 3.9M 16 2023 Q3 EARNINGS
Slide 17: 2023 Financial Guidance
2023 Financial Guidance INBRIJA U.S. Net Revenue $34M - $38M AMPYRA U.S. Net Revenue $65M - $70M Adjusted OpEx $93M - $98M Ending Cash Balance $39M - $44M 17 2023 Q3 EARNINGS
Slide 18: Priorities to Build Shareholder Value
Priorities to Build Shareholder Value ✓ Accelerate INBRIJA trajectory -Additional ex-U.S. INBRIJA agreements ✓ Maintain AMPYRA ✓ Continued fiscal discipline ✓ Communication with bondholders ✓ ARCUS collaborations 18 2023 Q3 EARNINGS
Slide 19: LIFE. SCIENCE.
LIFE. SCIENCE. °